Published in EMBO J on August 15, 2002
The power to reduce: pyridine nucleotides--small molecules with a multitude of functions. Biochem J (2007) 3.11
Ogt-dependent X-chromosome-linked protein glycosylation is a requisite modification in somatic cell function and embryo viability. Mol Cell Biol (2004) 2.56
Glucose-6-phosphate dehydrogenase, NADPH, and cell survival. IUBMB Life (2012) 1.70
Loss of Atrx affects trophoblast development and the pattern of X-inactivation in extraembryonic tissues. PLoS Genet (2006) 1.64
G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. Br J Haematol (2013) 1.53
Cellular metabolic and autophagic pathways: traffic control by redox signaling. Free Radic Biol Med (2013) 1.46
The return of metabolism: biochemistry and physiology of the pentose phosphate pathway. Biol Rev Camb Philos Soc (2014) 1.27
Control of hepatic nuclear superoxide production by glucose 6-phosphate dehydrogenase and NADPH oxidase-4. J Biol Chem (2011) 1.26
Overexpression of glucose-6-phosphate dehydrogenase is associated with lipid dysregulation and insulin resistance in obesity. Mol Cell Biol (2005) 1.24
Detection of haplotypes associated with prenatal death in dairy cattle and identification of deleterious mutations in GART, SHBG and SLC37A2. PLoS One (2013) 1.23
Regulation of the pentose phosphate pathway in cancer. Protein Cell (2014) 1.03
The Roles of Glutathione Peroxidases during Embryo Development. Front Mol Neurosci (2011) 1.03
Impact of glucose-6-phosphate dehydrogenase deficiency on the pathophysiology of cardiovascular disease. Am J Physiol Heart Circ Physiol (2012) 1.00
Glucose-6-phosphate dehydrogenase-deficient mice have increased renal oxidative stress and increased albuminuria. FASEB J (2009) 0.98
Reactivation of the inactive X chromosome in development and reprogramming. Cell Mol Life Sci (2012) 0.98
Glucose-6-phosphate dehydrogenase deficiency in transfusion medicine: the unknown risks. Vox Sang (2013) 0.96
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype. Clin Pharmacol Ther (2014) 0.90
Expression of X-linked genes in deceased neonates and surviving cloned female piglets. Mol Reprod Dev (2008) 0.90
Modulation of the pentose phosphate pathway induces endodermal differentiation in embryonic stem cells. PLoS One (2012) 0.87
Glucose 6-phosphate dehydrogenase deficiency enhances germ cell apoptosis and causes defective embryogenesis in Caenorhabditis elegans. Cell Death Dis (2013) 0.85
Serine arginine splicing factor 3 is involved in enhanced splicing of glucose-6-phosphate dehydrogenase RNA in response to nutrients and hormones in liver. J Biol Chem (2012) 0.83
The single active X in human cells: evolutionary tinkering personified. Hum Genet (2011) 0.83
A model of glucose-6-phosphate dehydrogenase deficiency in the zebrafish. Exp Hematol (2013) 0.80
Genomic copy number variation in Mus musculus. BMC Genomics (2015) 0.79
Parallel universes of Black Six biology. Biol Direct (2014) 0.79
Validation of Deleterious Mutations in Vorderwald Cattle. PLoS One (2016) 0.76
Brain glucose-6-phosphate dehydrogenase protects against endogenous oxidative DNA damage and neurodegeneration in aged mice. ACS Chem Neurosci (2013) 0.76
Coupling between Protein Stability and Catalytic Activity Determines Pathogenicity of G6PD Variants. Cell Rep (2017) 0.75
Impaired embryonic development in glucose-6-phosphate dehydrogenase-deficient Caenorhabditis elegans due to abnormal redox homeostasis induced activation of calcium-independent phospholipase and alteration of glycerophospholipid metabolism. Cell Death Dis (2017) 0.75
Simultaneous dual targeting of Par-4 and G6PD: a promising new approach in cancer therapy? Quintessence of a literature review on survival requirements of tumor cells. Cancer Cell Int (2016) 0.75
The Wnt-1 (int-1) proto-oncogene is required for development of a large region of the mouse brain. Cell (1990) 10.99
Promotion of trophoblast stem cell proliferation by FGF4. Science (1998) 8.02
Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature (1999) 6.50
Glucose-6-phosphate dehydrogenase deficiency. N Engl J Med (1991) 4.31
Perinatal lethality and defects in hindbrain development in mice homozygous for a targeted mutation of the zinc finger gene Krox20. Genes Dev (1993) 3.93
Essential role of Mash-2 in extraembryonic development. Nature (1994) 3.36
Staging of gastrulating mouse embryos by morphological landmarks in the dissecting microscope. Development (1993) 2.95
Genomic imprinting of Mash2, a mouse gene required for trophoblast development. Nat Genet (1995) 2.46
Glucose-6-phosphate dehydrogenase: a "housekeeping" enzyme subject to tissue-specific regulation by hormones, nutrients, and oxidant stress. FASEB J (1994) 2.35
Demonstration of somatic mutation and colonic crypt clonality by X-linked enzyme histochemistry. Nature (1988) 2.28
Point mutation in kit receptor tyrosine kinase reveals essential roles for kit signaling in spermatogenesis and oogenesis without affecting other kit responses. EMBO J (2000) 2.13
Murine embryonic stem cells without pig-a gene activity are competent for hematopoiesis with the PNH phenotype but not for clonal expansion. J Clin Invest (1997) 1.86
X-chromosome inactivation occurs at different times in different tissues of the post-implantation mouse embryo. Nat Genet (1993) 1.83
Hematologically important mutations: glucose-6-phosphate dehydrogenase. Blood Cells Mol Dis (2002) 1.76
Regulation of X-chromosome inactivation in development in mice and humans. Microbiol Mol Biol Rev (1998) 1.72
The hemolytic effect of primaquine. II. The natural course of the hemolytic anemia and the mechanism of its self-limited character. J Lab Clin Med (1954) 1.67
The chromosome make-up of mouse embryonic stem cells is predictive of somatic and germ cell chimaerism. Transgenic Res (1997) 1.54
The molecular basis of glucose-6-phosphate dehydrogenase deficiency. Trends Genet (1992) 1.33
An embryoprotective role for glucose-6-phosphate dehydrogenase in developmental oxidative stress and chemical teratogenesis. FASEB J (2000) 1.15
Human erythrocyte glucose 6-phosphate dehydrogenase: structure and function in normal and mutant subjects. Curr Top Hematol (1978) 1.14
Parental source of chromosome imprinting and its relevance for X chromosome inactivation. Differentiation (1984) 1.04
Metabolism of [14C]glucose by postimplantation mouse embryos in vitro. J Embryol Exp Morphol (1983) 1.04
Differential expression of alpha-fetoprotein genes on the inactive X chromosome in extraembryonic and somatic tissues of a transgenic mouse line. Nature (1986) 1.02
Malaria. Protecting against bad air. Science (2001) 0.97
Biochemical mechanisms of glucose-6-phosphate dehydrogenase deficiency. Proc Natl Acad Sci U S A (1978) 0.96
Human mutations in glucose 6-phosphate dehydrogenase reflect evolutionary history. FASEB J (2000) 0.95
Glucose-6 phosphate dehydrogenase mutations and haplotypes in various ethnic groups. Blood (1995) 0.95
Somatic-cell selection is a major determinant of the blood-cell phenotype in heterozygotes for glucose-6-phosphate dehydrogenase mutations causing severe enzyme deficiency. Am J Hum Genet (1996) 0.94
Human colonic stem cell mutation frequency with and without irradiation. J Pathol (1994) 0.93
"COMPLETE" ERYTHROCYTE GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY. Arch Intern Med (1964) 0.93
The CTLA-4 gene is expressed in placental fibroblasts. Mol Hum Reprod (1999) 0.92
In vitro analysis of glucose metabolism and embryonic growth in postimplantation rat embryos. Development (1987) 0.92
Inherited haemolytic states: glucose-6-phosphate dehydrogenase deficiency. Clin Haematol (1975) 0.91
Glucose 6-phosphate dehydrogenase mutations causing enzyme deficiency in a model of the tertiary structure of the human enzyme. Blood (1996) 0.87
New insights into G6PD deficiency. Br J Haematol (1996) 0.86
Metabolite utilization by isolated embryonic rat hearts in vitro. J Embryol Exp Morphol (1972) 0.85
New glucose-6-phosphate dehydrogenase mutations associated with chronic anemia. Blood (1995) 0.83
Expression of the maternally derived X chromosome in the mural trophoblast of the mouse. J Embryol Exp Morphol (1980) 0.83
Effects of excess glucose on mammalian post-implantation embryos. Int J Dev Biol (1997) 0.81
Glucose 6-phosphate dehydrogenase expression is less prone to variegation when driven by its own promoter. Gene (2001) 0.81
Genetic evidence that glycolysis is necessary for gastrulation in the mouse. Dev Dyn (1996) 0.81
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature (2010) 13.82
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell (2011) 10.50
Genomic instability in mice lacking histone H2AX. Science (2002) 10.23
Tenets of PTEN tumor suppression. Cell (2008) 8.61
Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell (2005) 7.75
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol (2012) 7.32
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell (2011) 7.02
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med (2006) 6.90
Does the ribosome translate cancer? Nat Rev Cancer (2003) 6.89
Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell (2007) 6.52
Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol (2007) 5.79
Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell (2007) 5.62
Essential role of Plzf in maintenance of spermatogonial stem cells. Nat Genet (2004) 5.55
NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell (2007) 5.20
In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell (2011) 5.19
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med (2004) 5.01
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90
Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood (2002) 4.88
Nucleophosmin and cancer. Nat Rev Cancer (2006) 4.82
Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell (2011) 4.49
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell (2009) 4.30
Subtle variations in Pten dose determine cancer susceptibility. Nat Genet (2010) 4.19
Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal (2010) 4.15
The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat Immunol (2008) 4.15
Role of nucleophosmin in embryonic development and tumorigenesis. Nature (2005) 4.09
The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev Cell (2005) 3.96
SUMO modification of Huntingtin and Huntington's disease pathology. Science (2004) 3.85
Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain. Development (2004) 3.75
Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature (2005) 3.75
PML targeting eradicates quiescent leukaemia-initiating cells. Nature (2008) 3.75
Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood (2005) 3.71
SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. Cancer Cell (2011) 3.71
Identification of a tumour suppressor network opposing nuclear Akt function. Nature (2006) 3.68
The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature (2008) 3.53
PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev (2008) 3.50
A continuum model for tumour suppression. Nature (2011) 3.48
A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest (2010) 3.47
Role of Nbs1 in the activation of the Atm kinase revealed in humanized mouse models. Nat Cell Biol (2005) 3.44
H2AX is required for chromatin remodeling and inactivation of sex chromosomes in male mouse meiosis. Dev Cell (2003) 3.42
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell (2012) 3.37
A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat Med (2012) 3.33
The role of PML in tumor suppression. Cell (2002) 3.28
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest (2009) 3.23
The mechanisms of PML-nuclear body formation. Mol Cell (2006) 3.22
PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science (2010) 3.21
Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science (2003) 3.18
Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst (2004) 3.17
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A (2010) 3.13
Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature (2010) 3.09
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood (2009) 3.02
PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature (2006) 3.01
Generation of functional multipotent adult stem cells from GPR125+ germline progenitors. Nature (2007) 3.01
Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nat Cell Biol (2009) 2.97
A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell (2006) 2.95
Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF. Science (2007) 2.92
Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol (2009) 2.91
Cytoplasmic PML function in TGF-beta signalling. Nature (2004) 2.89
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med (2008) 2.85
The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev (2006) 2.76
Pro-senescence therapy for cancer treatment. Nat Rev Cancer (2011) 2.75
PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell (2008) 2.66
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell (2015) 2.60
Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer (2013) 2.59
A quantitative measurement of the human somatic mutation rate. Cancer Res (2005) 2.55
Rescue of cardiac defects in id knockout embryos by injection of embryonic stem cells. Science (2004) 2.53
Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell (2003) 2.53
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov (2012) 2.53
Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood (2004) 2.52
A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res (2006) 2.50
PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol (2004) 2.45
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood (2007) 2.41
PML is a direct p53 target that modulates p53 effector functions. Mol Cell (2004) 2.40
Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell (2012) 2.39
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood (2007) 2.36
The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell (2013) 2.33
Promyelocytic leukemia protein mediates interferon-based anti-herpes simplex virus 1 effects. J Virol (2003) 2.33
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet (2013) 2.29
Plzf regulates germline progenitor self-renewal by opposing mTORC1. Cell (2010) 2.29
Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc Natl Acad Sci U S A (2003) 2.23
Congenital amegakaryocytic thrombocytopenia: clinical and biological consequences of five novel mutations. Haematologica (2007) 2.23
Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res (2011) 2.20
Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med (2012) 2.19
Tsc2-Rheb signaling regulates EphA-mediated axon guidance. Nat Neurosci (2010) 2.17
Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol (2002) 2.15
TCR-inducible PLZF transcription factor required for innate phenotype of a subset of gammadelta T cells with restricted TCR diversity. Proc Natl Acad Sci U S A (2009) 2.13
Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in permissive molecular environments. Proc Natl Acad Sci U S A (2013) 2.13
The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med (2007) 2.12
Causality and Chance in the Development of Cancer. N Engl J Med (2015) 2.10